Latest News
Analyst revises Oracle (ORCL) stock price target
Although Oracle Corp. (NYSE: NYSE) saw its market capitalization fall by $146.4 billion so far in 2026, hovering at $407.1 billion on September 2, Mark Moerdler, a Wall Street analyst at Bernstein Soc
Micron: This Cycle Might Shock Everyone
Micron Technology remains a compelling long-term investment, with fundamentals strengthening despite recent sector-driven stock volatility. MU benefits from surging AI memory demand, multi-year custom
U.S. government sides with OpenAI on issue of training LLMs on copyrighted material
In a lawsuit that the New York Times filed against OpenAI, the Trump administration has contributed a 20-page brief in defense of the ChatGPT maker's unlicensed use of copyrighted material to train it
ETF Acquisitions Surge: Goldman, Victory, & T. Rowe Price Expand
August 2026 was a blockbuster month for ETF acquisitions. As Todd Rosenbluth, head of research at VettaFi, recently highlighted, the ETF industry is firing on all cylinders, attracting massive inflows
Enhanced geothermal notches another win as Google buys 400 MW from Fervo
Geothermal energy company Fervo notched another win as Google agreed to buy nearly half a gigawatt of electricity to power a planned new data center in Utah.
EQT Corporation: A Rainy Day Idea
EQT Corporation offers both upstream exposure and significant midstream diversification. The company's midstream segment provides stable cash flow via long-term, take-or-pay contracts. EQT pursues a d
Paul Mueller Company: Even With A Decline In Backlog, It's Too Attractive To Ignore
Paul Mueller Company remains a strong buy due to compelling value, robust growth, and a pristine balance sheet. Despite a 21.8% revenue surge to $160.2M in H1 2026, net income and cash flows declined
Starbucks: The Turnaround Is Working, But The Stock Looks Fairly Valued
Starbucks Corporation is rated Hold as its valuation already reflects turnaround potential, balancing macro risks and ongoing strategic improvements. SBUX delivered 7.9% global comp sales growth, rais
Wall Street Lunch: Uber To Eliminate Up To 3,300 Jobs
Uber Technologies is cutting up to 10% of its workforce, streamlining management, and reducing remote roles to focus on core business efficiency. Credo Technology faces margin concerns post-earnings,
Wendy's Rally Fades After Trian Steps Back: Was It Ever Real?
For a few days in mid-August, Wendy's NASDAQ: WEN traded like a company about to be taken private. Reports surfaced on Aug. 12 that Trian Fund Management, Nelson Peltz's activist firm and a roughly 16
Kaplan Fox Encourages Investors of Planet Fitness, Inc. (PLNT) to Act Ahead of the Lead Plaintiff Deadline on September 14, 2026
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Planet Fitness, Inc. ("Planet Fitness" or the "Compa
Sprinklr, Inc. (CXM) Q2 2027 Earnings Call Transcript
Sprinklr, Inc. (CXM) Q2 2027 Earnings Call Transcript
StealthGas Inc. (GASS) Q2 2026 Earnings Call Prepared Remarks Transcript
StealthGas Inc. (GASS) Q2 2026 Earnings Call Prepared Remarks Transcript
Gold price will approach $5,000/oz in 2026, $5,300/oz in 2027 on ‘uncertainty, de-dollarization, and debasement concern' – RBC
Gold's recent price action has demonstrated that geopolitical instability, global de-dollarization and worries over U.S. dollar debasement are returning to the fore, and the yellow metal is now poised
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 2, 2026 /PRNewswire/ -- The Law Offices of Frank R.
Kaplan Fox Notifies Medline Inc. (MDLN) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Medline Inc. ("Medline" or the "Company") (NASDAQ: MDLN)
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
GitLab's Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
GitLab TodayGTLBGitLab$50.88 +5.79 (+12.84%) As of 12:09 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$18.73▼$55.55Price Target$51.88Add to WatchlistGitLab
Berger Montague PC Investigating Claims on Behalf of Investors in Hyliion Holdings Corp. (NYSE: HYLN) After Class Action Filing
PHILADELPHIA, Sept. 2, 2026 /PRNewswire/ -- Berger Montague PC, a leading national plaintiffs' law firm, announces a class action lawsuit against Hyliion Holdings Corp. (NYSE: HYLN) ("Hyliion" or the
Dow Jones: Yields Ease After ADP Miss, but Can the US 30 Hold Its Bounce?
Dow Jones buyers found support after soft ADP data eased yields, but oil and Fed hike odds leave Friday's payrolls as the next test.